Preliminary analysis of mortality associated with rituximab use in autoimmune diseases

Autoimmunity

Volumn 46, Issue 8, 2013, Pages 487-496

  Shetty, Shawn ^a   Ahmed, A R ^a  

^a Center for Blistering Diseases   (United States)

Author keywords

Autoimmune bullous diseases; Autoimmune disease; Fatal outcomes; Immunosuppression; Infection; Rituximab; Rituximab protocol for lymphoma; Rituximab protocol for rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BULLOUS PEMPHIGOID; CAUSE OF DEATH; DRUG MEGADOSE; EPIDERMOLYSIS BULLOSA ACQUISITA; FATALITY; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION SENSITIVITY; LYMPHOCYTE DEPLETION; MUCOUS MEMBRANE PEMPHIGOID; PEMPHIGUS; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; CAUSE OF DEATH; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84887434496     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.838563     Document Type: Article

References (137)

1. Edwards, J. C., M. J. Leandro, and G. Cambridge. 2002. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem. Soc. Trans. 30: 824-828 (Pubitemid 35001668)
2. Maloney, D. G., B. Smith, and A. Rose. 2002. Rituximab: mechanism of action and resistance. Semin. Oncol. 29: 2-9 (Pubitemid 34171789)
3. Weiner, G. J. 2010. Rituximab: mechanism of action. Semin. Hematol. 47: 115-123
4. Leget, G. A., and M. S. Czuczman. 1998. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10: 548-551 (Pubitemid 28502249)
5. Smolen, J. S., E. C. Keystone, P. Emery, et al.; Working Group on the Rituximab Consensus Statement. 2007. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66: 143-150 (Pubitemid 46226045)
6. Looney, R. J. 2005. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 44: ii13-ii17
7. Pers, J. O., C. Daridon, B. Bendaoud, et al. 2008. B-cell depletion and repopulation in autoimmune diseases. Clin. Rev. Allergy Immunol. 34: 50-55
8. Kazkaz, H., and D. Isenberg. 2004. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr. Opin. Pharmacol. 4: 398-402 (Pubitemid 38987068)
9. Dö rner, T., D. Isenberg, D. Jayne, et al.; International Roundtable on B cells as Therapeutic Target for Intervention. 2009. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 9: 82-89
10. Liu, G., K. A. Muili, V. V. Agashe, and J. A. Lyons. 2012. Unique B cell responses in B cell-dependent and B cell-independent EAE. Autoimmunity. 45: 199-209
11. Salinas, G. F., F. Braza, S. Brouard, et al. 2013. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin. Immunol. 146: 34-45
12. von Boehmer, H., and F. Melchers. 2010. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 11: 14-20
13. Isenberg, D. A. 2006. B cell targeted therapies in autoimmune diseases. J. Rheumatol. Suppl. 77: 24-28
14. Mease, P. J. 2008. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J. Rheumatol. 35: 1245-1255 (Pubitemid 352000767)
15. Eisenberg, R., and R. J. Looney. 2005. The therapeutic potential of anti-CD20 "what do B-cells do". Clin. Immunol. 117: 207-213 (Pubitemid 43005207)
16. Gorman, C., M. Leandro, and D. Isenberg. 2003. B cell depletion in autoimmune disease. Arthritis Res. Ther. 5: S17-S21 (Pubitemid 38239912)
17. Vital, E. M., A. C. Rawstron, S. Dass, et al. 2011. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 63: 603-608
18. Dass, S., A. C. Rawstron, E. M. Vital, et al. 2008. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58: 2993-2999
19. Besada, E., and J. C. Nossent. 2013. Infection risks during longterm rituximab therapy change over time. J. Rheumatol. 40: 203
20. Brinkman, I. H., M. A. van de Laar, T. L. Jansen, and E. N. van Roon. 2011. The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. Expert Opin. Drug Saf 10: 715-726
21. Morrison, L. H. 2004. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J. Am. Acad. Dermatol. 51: 817-819 (Pubitemid 39516904)
22. Tournadre, A., S. Amarger, P. Joly, et al. 2008. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab. Joint Bone Spine. 75: 728-729
23. Joly, P., H. Mouquet, J. C. Roujeau, et al. 2007. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med 357: 545-552 (Pubitemid 47236279)
24. Kim, J. H., Y. H. Kim, M. R. Kim, and S. C. Kim. 2011. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br. J. Dermatol 165: 646-651
25. Kanwar, A. J., D. Tsuruta, K. Vinay, et al. 2013. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J. Eur. Acad. Dermatol. Venereol. 27: e17-e23
26. Lunardon, L., K. J. Tsai, K. J. Propert, et al. 2012. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch. Dermatol. 148: 1031-1036
27. Colliou, N., D. Picard, F. Caillot, et al. 2013. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci. Transl. Med. 5: 175ra30
28. Lourari, S., C. Herve, V. Doffoel-Hantz, et al. 2011. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J. Eur. Acad. Dermatol. Venereol. 25: 1238-1240
29. Szabolcs, P., M. Reese, K. B. Yancey, et al. 2002. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 30: 327-329
30. Schmidt, E., C. S. Seitz, S. Benoit, et al. 2007. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol. 156: 352-356 (Pubitemid 46095965)
31. Mercader, P., J. M. Rodenas, A. Peña, and J. M. Mascaro Jr. 2007. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J. Eur. Acad. Dermatol. Venereol. 21: 1141-1142 (Pubitemid 47304640)
32. Le Roux-Villet, C., C. Prost-Squarcioni, M. Alexandre, et al. 2011. Rituximab for patients with refractory mucous membrane pemphigoid. Arch. Dermatol. 147: 843-849
33. Gürcan, H. M., D. B. Keskin, J. N. Stern, et al. 2009. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9: 10-25.
34. Choi, S. I., and E. Brahn. 2010. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity. 43: 478-492
35. Sanders, D. B., and A. Evoli. 2010. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 43: 428-435
36. Szilasi, M., J. Mátyus, I. File, et al. 2012. Association of ANCAassociated vasculitis-rheumatoid arthritis overlap syndrome in four patients: rituximab may be the right choice Autoimmunity. 45: 304-309
37. Ghanima, W., B. Godeau, D. B. Cines, and J. B. Bussel. 2012. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 120: 960-969
38. Schmidt, E., E. B. Bröcker, and M. Goebeler. 2008. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin. Rev. Allergy Immunol. 34: 56-64
39. Drugs Information Online. Rituxin. Available from: http://www.drugs.com/ pro/rituxan.html. Revised May 2013. Accessed on September 25, 2013
40. Furst, D. E., E. C. Keystone, J. Braun, et al. 2012. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann. Rheum. Dis. 71: i2-45
41. Rubbert-Roth, A. 2012. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 51: v38-v47
42. Guerry, M. J., P. Brogan, I. N. Bruce, et al. 2012. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51: 634-643
43. Tavazzi, E., P. Ferrante, and K. Khalili. 2011. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 17: 1776-1780
44. Martin-Garrido I, Carmona EM, Specks U, and Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest 144: 258-265
45. Shetty, S., and A. R. Ahmed. 2013. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J. Am. Acad. Dermatol. 68: 499-506
46. Shetty, S., and A. R. Ahmed. 2013. Treatment of bullous pemphigoid with rituximab: Critical analysis of the current literature. J. Drugs Dermatol. 12: 672-677
47. Zakka, L. R., S. S. Shetty, and A. R. Ahmed. 2012. Rituximab in the Treatment of Pemphigus Vulgaris. Dermatol. Ther. (Heidelb) 2: 17
48. Schmaldienst, S., and W. H. Horl. 1996. Bacterial infections during immunosuppression-immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. Nephrol. Dial. Transplant. 11: 1243-1245 (Pubitemid 26241408)
49. Cooper, N., and D. M. Arnold. 2010. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol. 149: 3-13
50. Popa, C., M. J. Leandro, G. Cambridge, and J. C. Edwards. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 46: 626-630 (Pubitemid 46523308)
51. Caporali, R., M. Caprioli, F. Bobbio-Pallavicini, et al. 2009. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun. Rev. 8: 591-594
52. Mihai, S., and C. Sitaru. 2007. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J. Cell. Mol. Med. 11: 462-481 (Pubitemid 47160231)
53. Scott, J. E., and A. R. Ahmed. 1998. The blistering diseases. Med. Clin. North Am. 82: 1239-1283 (Pubitemid 28512423)
54. Edwards, J. C., L. Szczepanski, J. Szechinski, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581 (Pubitemid 38758544)
55. Emery, P., R. Fleischmann, A. Filipowicz-Sosnowska, et al.; DANCER Study Group. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54: 1390-1400
56. Cohen, S. B., P. Emery, M. W. Greenwald, et al.; REFLEX Trial Group. 2006. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54: 2793-2806 (Pubitemid 44497758)
57. Mease, P. J., S. Cohen, N. B. Gaylis, et al. 2010. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J. Rheumatol. 37: 917-927
58. Emery, P., A. Deodhar, W. F. Rigby, et al. 2010. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann. Rheum. Dis. 69: 1629-1635
59. Keystone, E., R. Fleischmann, P. Emery, et al. 2007. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56: 3896-3908 (Pubitemid 350262316)
60. Bang, S. Y., C. K. Lee, Y. M. Kang, et al. 2012. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012: 565039
61. Tzaribachev, N., I. Koetter, J. B. Kuemmerle-Deschner, and J. Schedel. 2009. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J. 2: 6609
62. D́az-Lagares, C., S. Croca, S. Sangle, et al.; UK-BIOGEAS Registry. 2012. Efficacy of rituximab in 164 patients with biopsyproven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11: 357-364
63. Vigna-Perez, M., B. Hernández-Castro, O. Paredes-Saharopulos, et al. 2006. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8: R83
64. Catapano, F., A. N. Chaudhry, R. B. Jones, et al. 2010. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol. Dial. Transplant. 25: 3586-3592
65. Terrier, B., Z. Amoura, P. Ravaud, et al.; Club Rhumatismes et Inflammation. 2010. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62: 2458-2466
66. Merrill, J. T., C. M. Neuwelt, D. J. Wallace, et al. 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62: 222-233
67. Rovin, B. H., R. Furie, K. Latinis, et al.; LUNAR Investigator Group. 2012. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64: 1215-1226
68. Lindholm, C., K. Bö rjesson-Asp, K. Zendjanchi, et al. 2008. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J. Rheumatol. 35: 826-833 (Pubitemid 351747123)
69. Calderón Saldierna, R. E., M. A. Ramos Sánchez, Y. Mej́a Holgún, et al. 2010. Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus. Reumatol. Clin. 6: 82-85
70. Cartin-Ceba, R., J. M. Golbin, K. A. Keogh, et al. 2012. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 64: 3770-3778
71. Stone, J. H., P. A. Merkel, R. Spiera, et al.; RAVE-ITN Research Group. 2010. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N. Engl. J. Med. 363: 221-232
72. Wendt, M., I. Gunnarsson, J. Bratt, and A. Bruchfeld. 2012. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand. J. Rheumatol. 41: 116-119
73. Roll, P., E. Ostermeier, M. Haubitz, et al. 2012. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J. Rheumatol. 39: 2153-2156
74. Jones, R. B., J. W. Tervaert, T. Hauser, et al.; European Vasculitis Study Group. 2010. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363: 211-220
75. Jones, R. B., A. J. Ferraro, A. N. Chaudhry, et al. 2009. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156-2168
76. Puéchal, X., J. E. Gottenberg, J. M. Berthelot, et al.; Investigators of the AutoImmunity Rituximab Registry. 2012. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. Arthritis Care Res. (Hoboken). 64: 331-339
77. Terrier, B., D. Launay, G. Kaplanski, et al. 2010. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res. (Hoboken). 62: 1787-1795
78. Basse, G., D. Ribes, N. Kamar, et al. 2006. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant. Proc. 38: 2308-2310 (Pubitemid 46068544)
79. Visentini, M., M. Granata, M. L. Veneziano, et al. 2007. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin. Immunol 125: 30-33 (Pubitemid 47374540)
80. Visentini, M., S. Ludovisi, A. Petrarca, et al. 2011. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun. Rev. 10: 714-719
81. Ruch, J., B. McMahon, G. Ramsey, and H. C. Kwaan. 2009. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am. J. Hematol. 84: 120-122
82. Zaja, F., S. De Vita, C. Mazzaro, et al. 2003. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 101: 3827-3834 (Pubitemid 36857853)
83. Zaja, F., A. Bacigalupo, F. Patriarca, et al.; GITMO (Gruppo Italiano Trapianto Midollo Osseo). 2007. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40: 273-277 (Pubitemid 47108472)
84. Arnold, D. M., F. Dentali, M. A. Crowther, et al. 2007. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 146: 25-33 (Pubitemid 351650318)
85. Arnold, D. M., F. Dentali, M. A. Crowther, et al. 2011. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res. Ther. 13: R75
86. Ruggenenti, P., P. Cravedi, A. Chianca, et al. 2012. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23: 1416-1425
87. Chaumais, M. C., A. Garnier, F. Chalard, et al. 2009. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 24: 1753-1755
88. Carson, K. R., A. M. Evens, E. A. Richey, et al. 2009. Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 113: 4834-4840
89. Tesfa, D., S. Ajeganova, and H. Hägglund. 2011. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 63: 2209-2214
90. Besada, E., and J. C. Nossent. 2013. Infection risks during longterm rituximab therapy change over time. J. Rheumatol. 40: 203
91. Thiel J., U. Salzer, F. Hässler, et al. 2013. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity. [Epub ahead of print]. doi: 10.3109/08916934.2013. 798652
92. Selin, L. K., M. F. Wlodarczyk, A. R. Kraft, et al. 2011. Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity. 44: 328-347
93. Kelesidis, T., G. Daikos, D. Boumpas, and S. Tsiodras. 2011. Does rituximab increase the incidence of infectious complications A narrative review. Int. J. Infect. Dis. 15: e2-16
94. Stroopinsky, D., T. Katz, J. M. Rowe, et al. 2012. Rituximabinduced direct inhibition of T-cell activation. Cancer Immunol. Immunother. 61: 1233-1241
95. van de Veerdonk, F. L., B. Lauwerys, R. J. Marijnissen, et al 2011. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63: 1507-1516
96. Li, X., J. Braun, and B. Wei. (2011). Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. Autoimmunity. 44: 58-68
97. Kamburova, E. G., H. J. Koenen, K. J. Borgman, et al. 2013. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am. J. Transplant. 13: 1503-1511
98. Mariño, E., and S. T. Grey. (2012). B cells as effectors and regulators of autoimmunity. Autoimmunity. 45: 377-387
99. Ettinger, R., S. Kuchen, and P. E. Lipsky. 2008. The role of IL-21 in regulating B-cell function in health and disease. Immunol. Rev 223: 60-86 (Pubitemid 351986176)
100. Cerutti, A., I. Puga, and M. Cols. 2012. New helping friends for B cells. Eur. J. Immunol. 42: 1956-1968
101. Schett, G. (2008). Review: immune cells and mediators of inflammatory arthritis. Autoimmunity. 41: 224-229 (Pubitemid 351454993)
102. Casulo, C., J. Maragulia, and A. D. Zelenetz. 2013. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin. Lymphoma Myeloma Leuk. 13: 106-111
103. Boumans, M. J., R. M. Thurlings, D. M. Gerlag, et al. 2011. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 63: 3187-3194
104. Corcione, A., and V. Pistoia. 1997. B-cell-derived granulocytecolony stimulating factor (G-CSF). Methods. 11: 143-147 (Pubitemid 27207926)
105. Wolach, O., O. Shpilberg, and M. Lahav. 2012. Neutropenia after rituximab treatment: new insights on a late complication. Curr. Opin. Hematol. 19: 32-38
106. Tesfa, D., and J. Palmblad. 2011. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev. Hematol. 4: 619-625
107. Besada, E., W. Koldingsnes, and J. Nossent. 2012. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM. 105: 545-550
108. Terrier, B., M. Ittah, L. Tourneur, et al. 2007. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica. 92: e20-23
109. Puga, I., M. Cols, C. M. Barra, et al. 2011. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 13: 170-180
110. Teng, Y. K., E. W. Levarht, M. Hashemi, et al. 2007. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56: 3909-3918 (Pubitemid 350262317)
111. Thurlings, R. M., K. Vos, C. A. Wijbrandts, et al. 2008. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis. 67: 917-925 (Pubitemid 351956651)
112. Cassese, G., S. Arce, A. E. Hauser, et al. 2003. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171: 1684-1690. (Pubitemid 36966450)
113. Minges Wols, H. A., G. H. Underhill, G. S. Kansas, and P. L. Witte. 2002. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 169: 4213-4221 (Pubitemid 35178192)
114. Tavazzi, E., P. Ferrante, and K. Khalili. 2011. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 17: 1776-1780
115. Buch, M. H., J. S. Smolen, N. Betteridge, et al.; Rituximab Consensus Expert Committee. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70: 909-920
116. Ahmed, A. R., Z. Spigelman, L. A. Cavacini, and M. R. Posner 2006. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355: 1772-1779 (Pubitemid 44631360)
117. Ram, R., I. Ben-Bassat, O. Shpilberg, et al. 2009. The late adverse events of rituximab therapy-rare but there! Leuk. Lymphoma. 50: 1083-1095
118. Rios-Fernández, R., M. T. Gutierrez-Salmerón, J. L. Callejas-Rubio, et al. 2007. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br. J. Dermatol 157: 1271-1273 (Pubitemid 350119793)
119. Giezen, T. J., A. K. Mantel-Teeuwisse, M. J. ten Berg, et al. 2012. Rituximab-induced thrombocytopenia: a cohort study. Eur. J. Haematol. 89: 256-266
120. Dhand, S., and H. Bahrain. 2008. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Invest. 26: 913-915
121. Vial, T., and J. Descotes. 2003. Immunosuppressive drugs and cancer. Toxicology. 185: 229-240 (Pubitemid 36173740)
122. Mabrouk, D., H. M. Gürcan, D. B. Keskin, et al. 2010. Association between cancer and immunosuppressive therapy-analysis of selected studies in pemphigus and pemphigoid. Ann. Pharmacother. 44: 1770-1776
123. Lands, L. C. 2010. New therapies, new concerns: rituximabassociated lung injury. Pediatr. Nephrol. 25: 1001-1003
124. Wagner, S. A., A. C. Mehta, and D. A. Laber. 2007. Rituximabinduced interstitial lung disease. Am. J. Hematol. 82: 916-919
125. Garypidou, V., V. Perifanis, K. Tziomalos, and S. Theodoridou 2004. Cardiac toxicity during rituximab administration. Leuk. Lymphoma. 45: 203-204
126. Armitage, J. D., C. Montero, A. Benner, et al. 2008. Acute coronary syndromes complicating the first infusion of rituximab. Clin. Lymphoma Myeloma. 8: 253-255
127. Farag N., L. Mahran, K. Abou-Aisha, and M. El-Azizi. 2013. Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur. J. Clin. Microbiol. Infect. Dis. [Epub ahead of print]. doi: 10.1007/s10096-013-1861-5
128. Ru°zek, D., G. Dobler, and H. H. Niller. 2013. May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis BMC Infect. Dis. 13: 306
129. Pikman, R., and R. Ben-Ami. 2012. Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy. 4: 1869-1882
130. Krampe, K., A. Briem-Richter, L. Fischer, et al. 2010. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr. Transplant. 14: 67-71
131. Kumar, D., S. Gourishankar, T. Mueller, et al. 2009. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl. Infect. Dis. 11: 167-170
132. Kamel, S., S. O'Connor, N. Lee, et al. 2010. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk. Lymphoma. 51: 797-801
133. Huang, Y. C., C. J. Liu, C. Y. Liu, et al. 2011. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann. Hematol. 90: 1145-1151
134. Haeusler, G. M., M. A. Slavin, J. F. Seymour, et al. 2013. Lateonset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur. J. Haematol. 91: 157-163
135. Besada E., and J. C. Nossent Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis Clin. Rheumatol. 2013. [Epub ahead of print]. doi: 10.1007/s10067-013-2293-4
136. Teichmann, L. L., M. Woenckhaus, C. Vogel, et al. 2008. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 47: 1256-1257 (Pubitemid 352038242)
137. van Vollenhoven R. F., P. Emery, C. O. Bingham, 3rd, et al. 2012. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. [Epub ahead of print]. doi: 10.1136/annrheumdis- 2012-201956